Delivering an ASM would simply not be possible without the ongoing and dedicated support
of our industry partners, sponsors and exhibitors.
Click on the logos below to find out more about the organisations
whose partnerships are helping to bring your annual industry meetings to life.
The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
We are a leader in the treatment of iron deficiency and iron deficiency anaemia where our products treat over half a million Australian patients annually.
Located in Melbourne and head-quartered in Switzerland, we are a mid-sized pharmaceutical company actively engaged with patients advocates healthcare professionals and policy makers.
Vifor Pharma is proud to sponsor local medical education and invest in local research and development to help patients to lead better, healthier lives.
Find out more at www.boehringer-ingelheim.com.au and www.lilly.com.au
We maintain that pioneering spirit today through our unparalleled innovation with new therapies like expanded haemodialysis (HDx) and remote patient management (Sharesource).
Sharesource has been documented to simplify the delivery of care and improve patient outcomes using a two-way, cloud-based technology for peritoneal dialysis
patients. Sharesource creates a connected home therapy experience that is a safe and effective way to manage patients remotely.
Whilst HDx takes us a step closer to the natural kidney and represents a unique and significant advance in haemodialysis. HDx demonstrates superior removal of large middle molecules (25kDa to <60kDa), many of which are linked to the development of inflammation, cardiovascular disease and other co-morbidities in dialysis patients. HDx opens a new door for dialysis patients with a determined effort to improve patient outcomes past the limitations of current dialysis technology.
As Australia’s only local manufacturer of “Australian Made” peritoneal dialysis solutions, we are proud to invest in local medical innovation and support local hospitals, healthcare
professionals and patients.
Baxter Renal Care … pioneering dialysis therapies to save and sustain lives.
With our ethos of CHANGING TOMORROW™, Astellas is committed to exploring therapeutic areas in which there is a vital need for treatments that improve and lengthen patients’ lives. We’re not in the business of making ‘me too’ medicines. We strive to develop therapies that are first-in-class and best-in-class treatments that offer patients and their doctors genuinely new options for improving care.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.
Evolve aims to reduce low-value care by supporting physicians to be leaders in changing clinical behaviour for better patient care. Evolve ‘Top-Five’ recommendations on low-value practices are developed through a rigorous, peer-reviewed process led by clinical experts, informed by evidence and guided by consultation.
Evolve enables physicians to:
• safely and responsibly phase out low-value tests, treatments and procedures, where appropriate
• enhance the safety and quality of healthcare
• provide high-value care to patients based on evidence and expertise, and
• influence the best use of health resources, reducing wasted expenditure and the carbon footprint of the healthcare system.
Roche is one of the world’s largest biotech companies, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also a world leader in in-vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them antibiotics, antimalarials and cancer medicines. For the eleventh consecutive year, Roche has been recognised as one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2019 employed more than 98,000 people worldwide. In 2020, Roche invested around 10.8 billion US Dollars in research and development worldwide, including over AUD $46million in pharmaceuticals in Australia. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
Roche’s pharmaceutical division in Australia employs over 300 people who are dedicated to pioneering life-changing healthcare for every Australian via the clinical development, registration, sales, marketing and distribution of innovative pharmaceutical medicines. Australian patients have access to around 40 Roche medicines and Roche is a continued leader in oncology.
For more information, please visit www.roche-australia.com.
For more information visit alexion.com/worldwide/Australia
With our ethos of CHANGING TOMORROW™, Astellas is committed to exploring therapeutic areas in which there is a vital need for treatments that improve and lengthen patients’ lives. We’re not in the business of making ‘me too’ medicines. We strive to develop therapies that are first-in-class and best-in-class treatments that offer patients and their doctors genuinely new options for improving care.
ANZSN and ANZPNA Tonya Kara Paediatric Research Award
Kidney Health Australia Clinical Science Award and the ANZSN and Kidney Health Australia Environmental Research Award
With 1.5 million Australians unaware they have the early signs of kidney disease, early detection continues to be a key driver for Kidney Health Australia, with a focus on awareness raising activities targeting those at risk, as well as educating the primary care sector on the earlier diagnosis and treatment of kidney disease.
Research into kidney disease also continues to be a key focus, with the organization working with the clinical and research community to support treatment improvements and innovations so that one day, every Australian can enjoy good kidney health.
For more information visit kidney.org.au
ANZSN and Dietitians Australia Nutrition Research Award
This site uses cookies. Find out more about cookies and how you can refuse them.